Overview

A Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous microtracer dose administration of 100 microgram (mcg) (approximately 1 microcurie [mcCi]) of [14C]-TAK-906 in Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a single oral (solution) administration of 50 mg (approximately 100 mcCi) of [14C]-TAK-906 in Period 2 (absorption, distribution, metabolism, and elimination [ADME]).
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.